Trial · NCT00306202
Results by group889
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 889
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Recommended Phase II Dose of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia | Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | 60 | mg/m^2 QD | ||
| Recommended Phase II Dose of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia | Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose | 80 | mg/m^2 QD | ||
| Recommended Phase II Dose of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia | Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose | NA | mg/m^2 QD | ||
| Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. | Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2) | Drug-Related Deaths | 0 | participants | |
| Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. | Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2) | Drug-Related Deaths | 0 | participants | |
| Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2) | Drug-Related Deaths | 0 | participants | |
| Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2) | Drug-Related Deaths | 0 | participants | |
| Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. | Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2) | Drug-Related Deaths | 0 | participants | |
| Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. | Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2) | Drug-Related Deaths | 0 | participants | |
| Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. | Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2) | Drug-Related Deaths | 0 | participants | |
| Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. | Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2) | Drug-Related Deaths | 0 | participants | |
| Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. | Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2) | Drug-Related SAEs | 1 | participants | |
| Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. | Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2) | Drug-Related SAEs | 1 | participants | |
| Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2) | Drug-Related SAEs | 2 | participants | |
| Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. | Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2) | Drug-Related SAEs | 3 | participants | |
| Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. | Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2) | Drug-Related SAEs | 2 | participants | |
| Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. | Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2) | Drug-Related SAEs | 2 | participants | |
| Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. | Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2) | Drug-Related SAEs | 2 | participants | |
| Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. | Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2) | Drug-Related SAEs | 2 | participants | |
| Number of Participants With Related Deaths, Serious Adverse Events (SAEs), and Adverse Events (AEs) by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. | Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2) | Drug-Related AEs Leading to Discontinuation | 0 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00306202/results